BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Upgraded by Zacks Investment Research to “Hold”

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Friday, reports.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

OTCMKTS BVNRY remained flat at $$7.36 during trading on Friday. 396 shares of the company’s stock traded hands, compared to its average volume of 133. The company has a quick ratio of 5.84, a current ratio of 6.15 and a debt-to-equity ratio of 0.17. BAVARIAN NORDIC/S has a twelve month low of $5.92 and a twelve month high of $10.61.

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) last posted its quarterly earnings results on Wednesday, May 22nd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). BAVARIAN NORDIC/S had a negative net margin of 126.80% and a negative return on equity of 19.43%. The business had revenue of $19.29 million for the quarter, compared to analysts’ expectations of $21.15 million. Sell-side analysts predict that BAVARIAN NORDIC/S will post -0.56 earnings per share for the current fiscal year.


Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.

Read More: Range Trading

Get a free copy of the Zacks research report on BAVARIAN NORDIC/S (BVNRY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with's FREE daily email newsletter.